Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)—A randomized controlled trial

Highlights • Sepranolone (UC1010) is a GABAA modulating steroid antagonist to the progesterone metabolite allopregnanolone, which is probably causing the negative mood in women with premenstrual dysphoric disorder (PMDD). • In this randomized placebo-controlled parallel group trial UC1010 treatment during the premenstrual phase reduced negative mood symptoms significantly better than placebo in women with a well-defined PMDD. • The effect size was comparable to that of SSRIs and drospirenone containing oral contraceptives. • UC1010 was well tolerated and deemed safe.